7-氧杂螺[3.5]壬-2-基甲胺 | 1440962-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 7-氧杂螺[3.5]壬-2-基甲胺
• 英文名称: 7-oxaspiro[3.5]nonan-2-yl-methanamine
• 英文别名: 7-Oxaspiro[3.5]nonan-2-ylmethanamine
• CAS: 1440962-10-6
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: RTSFVTSFONHDFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氟-3-硝基苯磺酰胺 、 7-氧杂螺[3.5]壬-2-基甲胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以55%的产率得到4-(7-oxaspiro[3.5]nonan-2-yl-methylamino)-3-nitrobenzenesulfonamide
  参考文献：
  名称：

  [EN] NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR
  [FR] FORMULATION DE NANOPARTICULES D'INHIBITEUR DE LA BCL-2

  摘要：

  描述了各种白蛋白纳米颗粒Bcl-2抑制剂配方，以及使用它们治疗由细胞过度增殖所表征的疾病的方法，例如癌症和肿瘤。在各种实施例中，这种Bcl-2抑制剂配方包含白蛋白和以下化合物的化合物（I）或其药用可接受的盐，其中化合物（I）中的变量在此处定义。

  公开号：

  WO2021007303A1

文献信息

• [EN] BENZAMIDE COMPOUNDS<br/>[FR] COMPOSÉS BENZAMIDE
  申请人：ZENO ROYALTIES & MILESTONES LLC

  公开号：WO2019139902A1

  公开（公告）日：2019-07-18

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

  本文提供了化学式(I)的化合物。这些化合物以及其药用盐和组合物可用于治疗疾病或病况，包括由细胞过度增殖引起的病况，如癌症和肿瘤，以及病毒感染如HIV。
• Benzamide compounds
  申请人：Recurium IP Holdings, LLC

  公开号：US11318134B2

  公开（公告）日：2022-05-03

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.

  本研究提供了具有式(I)的化合物。此类化合物、及其药学上可接受的盐和组合物，可用于治疗各种疾病或病症，包括以细胞过度增殖为特征的疾病，如癌症和肿瘤，以及病毒性感染，如HIV。
• BENZAMIDE COMPOUNDS
  申请人：Recurium IP Holdings, LLC

  公开号：US20200339605A1

  公开（公告）日：2020-10-29

  Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
• NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR
  申请人：Recurium IP Holdings, LLC

  公开号：US20220273666A1

  公开（公告）日：2022-09-01

  Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.